These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15899624)

  • 21. Trastuzumab versus lapatinib: the cardiac side of the story.
    Azim H; Azim HA; Escudier B
    Cancer Treat Rev; 2009 Nov; 35(7):633-8. PubMed ID: 19640652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
    Belkacémi Y; Gligorov J; Mauriac L; Azria D
    Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab.
    Knobloch K; Tepe J; Lichtinghagen R; Luck HJ; Vogt PM
    Int J Cardiol; 2008 Mar; 125(1):113-5. PubMed ID: 17400308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased?
    Morabito A; Piccirillo MC; De Maio E; Di Maio M; Perrone F
    J Clin Oncol; 2009 Sep; 27(27):e123; author reply e124-5. PubMed ID: 19687322
    [No Abstract]   [Full Text] [Related]  

  • 25. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.
    Tarantini L; Cioffi G; Gori S; Tuccia F; Boccardi L; Bovelli D; Lestuzzi C; Maurea N; Oliva S; Russo G; Faggiano P;
    J Card Fail; 2012 Feb; 18(2):113-9. PubMed ID: 22300778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.
    van Hasselt JG; Boekhout AH; Beijnen JH; Schellens JH; Huitema AD
    Clin Pharmacol Ther; 2011 Jul; 90(1):126-32. PubMed ID: 21633346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
    Fiúza M
    Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
    Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
    Telli ML; Hunt SA; Carlson RW; Guardino AE
    J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
    Burstein HJ; Sun Y; Dirix LY; Jiang Z; Paridaens R; Tan AR; Awada A; Ranade A; Jiao S; Schwartz G; Abbas R; Powell C; Turnbull K; Vermette J; Zacharchuk C; Badwe R
    J Clin Oncol; 2010 Mar; 28(8):1301-7. PubMed ID: 20142587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
    Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
    Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
    Untch M; Muscholl M; Tjulandin S; Jonat W; Meerpohl HG; Lichinitser M; Manikhas AG; Coumbos A; Kreienberg R; du Bois A; Harbeck N; Jackisch C; Müller V; Pauschinger M; Thomssen C; Lehle M; Catalani O; Lück HJ
    J Clin Oncol; 2010 Mar; 28(9):1473-80. PubMed ID: 20177030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
    Suter TM; Procter M; van Veldhuisen DJ; Muscholl M; Bergh J; Carlomagno C; Perren T; Passalacqua R; Bighin C; Klijn JG; Ageev FT; Hitre E; Groetz J; Iwata H; Knap M; Gnant M; Muehlbauer S; Spence A; Gelber RD; Piccart-Gebhart MJ
    J Clin Oncol; 2007 Sep; 25(25):3859-65. PubMed ID: 17646669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 36. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
    Cortes J; Di Cosimo S; Climent MA; Cortés-Funes H; Lluch A; Gascón P; Mayordomo JI; Gil M; Benavides M; Cirera L; Ojeda B; Rodríguez CA; Trigo JM; Vazquez J; Regueiro P; Dorado JF; Baselga J;
    Clin Cancer Res; 2009 Jan; 15(1):307-14. PubMed ID: 19118059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
    Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
    J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
    Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
    J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
    Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
    Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab-induced cardiotoxicity.
    Moss LS; Starbuck MF; Mayer DK; Harwood EB; Glotzer J
    Oncol Nurs Forum; 2009 Nov; 36(6):676-85. PubMed ID: 19887355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.